Quifenadine hydrochloride is a non-sedating antihistamine that was initially investigated for the treatment of allergic rhinitis. Its synthesis involves a series of reactions, starting with a substituted pyridine derivative. Quifenadine hydrochloride acts as an antagonist of the H1 receptor, blocking the action of histamine and reducing allergic symptoms. However, despite its promising activity, it was not commercially successful due to concerns about its pharmacokinetic profile and potential side effects. Research on quifenadine hydrochloride has focused on its potential applications in treating various allergic conditions, including seasonal allergic rhinitis and chronic urticaria. Studies have explored its efficacy, safety, and mechanisms of action in different populations. While its development as a therapeutic agent has been discontinued, quifenadine hydrochloride remains a subject of research, particularly in the context of understanding the structure-activity relationships of antihistamines and exploring alternative routes of administration.'
| ID Source | ID |
|---|---|
| PubMed CID | 115027 |
| CHEMBL ID | 1510616 |
| SCHEMBL ID | 11613936 |
| MeSH ID | M0312616 |
| Synonym |
|---|
| 3-quinuclidinemethanol, alpha,alpha-diphenyl-, hydrochloride |
| fencarol |
| alpha,alpha-diphenyl-3-quinuclidinemethanol, hydrochloride |
| phencarol |
| quifenadine hydrochloride |
| fenkarol |
| 1-azabicyclo(2.2.2)octane-3-methanol, alpha,alpha-diphenyl-, hydrochloride |
| smr000289426 |
| MLS000765321 |
| AKOS005111025 |
| 10447-38-8 |
| 1-azabicyclo[2.2.2]oct-3-yl(diphenyl)methanol hydrochloride |
| unii-6wsk4828ll |
| 6wsk4828ll , |
| diphenyl(quinuclidin-3-yl)methanol hydrochloride |
| FT-0682664 |
| AM84319 |
| SCHEMBL11613936 |
| 1-azabicyclo[2.2.2]oct-3-yl(diphenyl)methanol hydrochloride (1:1) |
| CHEMBL1510616 |
| quifenadine hydrochloride [who-dd] |
| 3-quinuclidinemethanol, .alpha.,.alpha.-diphenyl-, hydrochloride |
| 1-azabicyclo(2.2.2)octane-3-methanol, .alpha.,.alpha.-diphenyl-, hydrochloride (1:1) |
| 1-azabicyclo(2.2.2)octane-3-methanol, .alpha.,.alpha.-diphenyl-, hydrochloride |
| AKOS030507569 |
| sr-01000323054 |
| SR-01000323054-1 |
| (quinuclidin-3-yl)diphenylcarbinol hydrochloride |
| diphenyl(quinuclidin-3-yl)methanolhydrochloride |
| ,-diphenyl-3-quinuclidinemethanol hydrochloride;,-diphenyl-3-quinuclidinemethanol hydrochloride |
| 1-azabicyclo[2.2.2]oct-3-yl(diphenyl)methanol hydrochloride;1-azabicyclo[2.2.2]oct-3-yl(diphenyl)methanol hydrochloride |
| alpha,alpha-diphenyl-3-quinuclidinemethanol hydrochloride;alpha,alpha-diphenyl-3-quinuclidinemethanol hydrochloride |
| (3-quinuclidinyl)diphenylcarbinolhydrochloride |
| Q27265638 |
| A927551 |
| (1-azabicyclo[2.2.2]octan-3-yl)(diphenyl)methanol--hydrogen chloride (1/1) |
| DTXSID30908989 |
| 1-azabicyclo[2.2.2]octan-3-yl(diphenyl)methanol;hydrochloride |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ClpP | Bacillus subtilis | Potency | 31.6228 | 1.9953 | 22.6730 | 39.8107 | AID651965 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 18.3489 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| TDP1 protein | Homo sapiens (human) | Potency | 13.9711 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 100.0000 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 0.3548 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.76) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||